

Personalized Medicine

USING GENETIC INFORMATION TO HELP COMBAT CANCER

Cancer by the Numbers



There are more than

100 TYPES OF CANCERSⁱ

Each year, more than **14 million people worldwide** learn they have cancer.ⁱⁱ

1 in 2 men

diagnosed with cancer in their lifetimeⁱⁱⁱ

1 in 3 women

MORE THAN 8 MILLION

die from the disease per year.^{iv}

The World Health Organization projects that **without immediate action** the global number of deaths from cancer will increase by

NEARLY 80% BY 2030.^{iv}

Tailoring Treatment

When it comes to cancer treatment, **1 SIZE DOES NOT FIT ALL.**



WHAT IS PERSONALIZED MEDICINE?

An approach that uses advanced tests to help **tailor diagnosis, treatment and disease prevention based on a patient's genetic makeup.^v**

Currently, **ONCOLOGY** is a major driver of personalized medicine, **representing nearly 70% of the field.^{vi}**

70%

Cancer Therapy Effectiveness

A few small studies about targeted therapies for melanoma, NSCLC* and gastric cancers have shown responses **ranging from 50% and above in patients.^{vii}**

*Non-small cell lung cancer

Molecular tests may allow doctors to provide more **personalized treatment approaches** to manage cancer.

Unlocking New Therapies

Doctors can order tests known as

COMPANION DIAGNOSTICS (CDx)

to identify patients who are most likely

to benefit from a particular

DRUG TREATMENT.^{viii}



CDx tests are an important tool that may help doctors **IMPROVE PATIENT OUTCOMES.**

CDx helps doctors to:^{ix}

- Identify patients who may respond to specific treatments
- Reduce patient exposure to less effective treatments

Abbott's Leadership

PERSONALIZED MEDICINE AREAS OF FOCUS

breast lung colorectal bladder
brain lung blood prostate
bladder

Current CDx tests on market

For non-small cell lung cancer patients with ALK gene mutations

For breast cancer patients with HER-2 gene amplifications

Personalized medicine is gaining strong traction in healthcare and Abbott is helping to lead the way.

Abbott is helping to develop diagnostics that may identify patients for targeted cancer therapies through:

- Multiple CDx programs with leading pharmaceutical partners
- Advanced discussions with numerous potential partners

To learn more visit www.AbbottCDx.com

ⁱ http://www.niehs.nih.gov/health/materials/cancer_and_the_environment_508.pdf

ⁱⁱ http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

ⁱⁱⁱ <http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer>

^{iv} <http://www.cdc.gov/cancer/dcpo/resources/features/worldcancerday/>

^v <http://www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/ucm20041021.htm>

^{vi} Accessed 3.25.14.

^{vii} GENReports: Market & Tech Analysis. "Cancer Personalized Medicine." Enal Razvi, Ph.D., 2013.

^{viii} http://www.nature.com/nm/journal/v19/n11/fig_tab/nm.3388_F4.html

^{ix} <http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm>

^x <http://obroncology.com/obrgreen/print/Companion-Diagnostics-Are-Driving-Support-in-the-Evolving-Regulatory-Landscape>



© 2014 Abbott Laboratories, Abbott Park, Illinois, USA